$GOSS News

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $5 Price Target

Gossamer Bio, Inc. 2026 Q1 - Results - Earnings Call Presentation

Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript

Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript

Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase Warrants

Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate

Cantor Fitzgerald Downgrades Gossamer Bio to Neutral

Gossamer Bio Q4 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.799M Beat $7.522M Estimate

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $5

Oppenheimer Maintains Outperform on Gossamer Bio, Lowers Price Target to $3

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension - Slideshow

These Analysts Slash Their Forecasts On Gossamer Bio

Wedbush Downgrades Gossamer Bio to Neutral, Lowers Price Target to $1

Barclays Downgrades Gossamer Bio to Underweight, Lowers Price Target to $0.3

Leerink Partners Downgrades Gossamer Bio to Market Perform, Lowers Price Target to $1

12 Health Care Stocks Moving In Monday's After-Market Session

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Gossamer Bio shares are trading lower. The company announced topline results for the PROSERA Phase 3 Study of seralutinib in patients with PAH.

Gossamer Bio shares are trading lower. The company announced topline results for the PROSERA Phase 3 Study of seralutinib in patients with PAH.